文献速递间质性肺疾病

GLPG1690治疗特发性肺纤维化的FLORA 2a期试验

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2018-05-20

FLORA是一项随机双盲安慰剂对照2a期研究,在意大利、乌克兰和英国17个中心纳入23例特发性肺纤维化(IPF)患者,按1:3随机接受安慰剂或600 mg口服GLPG1690每日一次治疗12周。主要结局为安全性、耐受性、药代动力学和药效动力学。结果显示GLPG1690总体安全性与安慰剂相似,血浆LPA C18:2浓度持续下降,支持进一步开发。

要点

  • GLPG1690 600 mg每日一次治疗12周,安全性与安慰剂相似,不良事件多为轻中度。
  • GLPG1690组血浆LPA C18:2浓度持续下降,药代和药效特征与健康对照相似。
  • 第12周FVC平均变化GLPG1690组25 mL,安慰剂组-70 mL,研究支持进一步开发。

核心结论

  • 研究结果支持将GLPG1690作为IPF新型治疗药物进一步开发。

研究设计与样本

  • 随机、双盲、安慰剂对照2a期研究,在意大利、乌克兰和英国17个中心进行。
  • 纳入40岁及以上、不吸烟、未使用吡非尼酮或尼达尼布且中心确诊的IPF患者。
  • 按1:3随机分配接受安慰剂或600 mg口服GLPG1690每日一次,治疗12周。
  • 主要结局为安全性(不良事件)、耐受性、药代动力学和药效动力学,肺功能为次要结局。

主要发现

  • 共筛查72例患者,23例入组八个中心(乌克兰六个、英国两个),安慰剂组6例,GLPG1690组17例。
  • 安慰剂组4例(67%)和GLPG1690组11例(65%)发生治疗中出现的不良事件,多为轻中度。
  • GLPG1690组2例(12%)事件被判定与治疗相关;无患者死亡。
  • 第12周FVC较基线平均变化:GLPG1690组25 mL(95%CI -75至124),安慰剂组-70 mL(95%CI -208至68 mL)。

关键数值与推荐

  • GLPG1690组血浆LPA C18:2浓度持续下降。
  • GLPG1690的药代动力学和药效动力学特征与健康对照中先前所示相似。

临床怎么用

  • GLPG1690 600 mg每日一次治疗12周在IPF患者中总体安全且耐受良好。
  • 药效学标志物LPA C18:2持续下降支持靶点 engagement,但FVC变化置信区间宽,需进一步研究验证。

局限性

  • 2a期探索性研究样本量小(共23例),主要结局为安全性和药代/药效,肺功能为次要结局。
  • 研究仅纳入未使用吡非尼酮或尼达尼布的非吸烟IPF患者,结果外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. People with IPF have increased concentrations of autotaxin in lung tissue and lysophosphatidic acid (LPA) in bronchoalveolar lavage fluid and exhaled condensate. GLPG1690 (Galapagos, Mechelen, Belgium) is a novel, potent, selective autotaxin inhibitor with good oral exposure. We explored the effects of GLPG1690 in patients with IPF. METHODS: This was a randomised, double-blind, placebo-controlled phase 2a study done in 17 centres in Italy, Ukraine and the UK. Eligible patients were aged 40 years or older, non-smokers, not taking pirfenidone or nintedanib, and had a centrally confirmed diagnosis of IPF. We used a computer-generated randomisation schedule to assign patients 1:3 to receive placebo or 600 mg oral GLPG1690 once daily for 12 weeks. The primary outcomes were safety (adverse events), tolerability, pharmacokinetics, and pharmacodynamics. Spirometry was assessed as a secondary outcome. This trial is registered with ClinicalTrials.gov, number NCT02738801. FINDINGS: Between March 24, 2016, and May 2, 2017, 72 patients were screened., of whom 49 were ineligible and 23 were enrolled in eight centres (six in Ukraine and two in the UK). Six patients were assigned to receive placebo and 17 to receive GLPG1690. 20 patients completed the study after one in each group discontinued because of adverse events and one in the GLPG1690 group withdrew consent. Four (67%) patients in the placebo group and 11 (65%) in the GLPG1690 group had treatment-emergent adverse events, most of which were mild to moderate. The most frequent events in the GLPG1690 group were infections and infestations (ten events) and respiratory, thoracic, and mediastinal disorders (eight events) with no apparent differences from the placebo group. Two (12%) patients in the GLPG1690 group had events that were judged to be related to treatment. Serious adverse events were seen in two patients in the placebo group (one had a urinary tract infection, acute kidney injury, and lower respiratory tract infection and the other had atrioventricular block, second degree) and one in the GLPG1690 group (cholangiocarcinoma that resulted in discontinuation of treatment). No patients died. The pharmacokinetic and pharmacodynamic profiles of GLPG1690 were similar to those previously shown in healthy controls. LPA C18:2 concentrations in plasma were consistently decreased. Mean change from baseline in forced vital capacity at week 12 was 25 mL (95% CI -75 to 124) for GLPG1690 and -70 mL (-208 to 68 mL) for placebo. INTERPRETATION: Our findings support further development of GLPG1690 as a novel treatment for IPF. FUNDING: Galapagos.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018. PMID: 29792287. doi:10.1016/S2213-2600(18)30181-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。